655 related articles for article (PubMed ID: 23096164)
21. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
22. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
24. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
25. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
26. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
27. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
28. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
29. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes.
Moreau M; Raguin O; Vrigneaud JM; Collin B; Bernhard C; Tizon X; Boschetti F; Duchamp O; Brunotte F; Denat F
Bioconjug Chem; 2012 Jun; 23(6):1181-8. PubMed ID: 22519915
[TBL] [Abstract][Full Text] [Related]
30. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
Hoang B; Ekdawi SN; Reilly RM; Allen C
Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
[TBL] [Abstract][Full Text] [Related]
31. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
32. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
33. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
34. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
[TBL] [Abstract][Full Text] [Related]
36. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
37. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
39. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.
Chan C; Scollard DA; McLarty K; Smith S; Reilly RM
EJNMMI Res; 2011 Aug; 1(1):15. PubMed ID: 22214307
[TBL] [Abstract][Full Text] [Related]
40. Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR.
Kwon LY; Cai Z; Al-Mahrouki A; Reilly RM
iScience; 2024 May; 27(5):109750. PubMed ID: 38711454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]